Wednesday, July 25, 2018

23andMe Gets $300M From GlaxoSmithKline

Mountain View-based 23andMe, the provider of genetic testing services, has scored $300M in a strategic funding from GlaxoSmithKline, the two said on Tuesday. As part of the investment, the two said they are in a four-year collaboration deal to use 23andMe's genetic data, where GSK will become 23andMe's exclusive collaborator for drug target discovery programs. More information »